Novo Nordisk, PanGenomic Health and Pfizer - Who are the winners of the digital health revolution?

Novo Nordisk – More than just medicines

Novo Nordisk is resolutely pushing ahead with its digital offensive. Going beyond pure pharmaceutical products, the Company is building a comprehensive digital ecosystem designed to accompany and enhance therapies. For patients with obesity or diabetes, this means access to apps and online platforms that offer support with nutrition, fitness, and treatment adherence. Smart insulin pens automatically document dosages and synchronize data with health apps. The goal is clear: to improve treatment success in the long term through digital support and to evolve from a pure drug supplier to a holistic health partner.

The former blockbusters Wegovy and Ozempic are facing a more challenging environment. The US market, formerly the main growth driver, is showing initial signs of saturation; prescription numbers have recently declined noticeably. Competitive pressure from Eli Lilly's products and the approaches of other pharmaceutical companies is increasing noticeably. Although demand for GLP-1 therapies remains robust overall, the hypergrowth phase appears to be over. For Novo Nordisk, this means shifting from a phase of exceptional growth to a more sustainable but moderate pace of expansion.

Under new CEO Mike Doustdar, Novo Nordisk is undergoing a profound structural change. The announced global restructuring, which will see around 11% of jobs cut, aims to make the Company more agile and focused. The associated one-time costs are considerable, but significant annual savings are expected from 2026 onwards. Management intends to channel the resources freed up into the growth areas of diabetes and obesity, as well as into the innovation pipeline. This strategic reset is intended to make the Company more efficient in order to survive in the face of intensifying competition in the long term. The share is currently trading at EUR 49.06.

PanGenomic Health – Data-driven personalization

PanGenomic Health is emerging as a leading player in the digital health sector. The Company relies on AI-powered platform technology to develop personalized health solutions. The focus is particularly on plant-based therapies and mental health, using a combination of genetic data, lifestyle inputs, and real-time health metrics. The result is highly customized health recommendations tailored precisely to each user. PanGenomic thus specifically addresses critical gaps in today's healthcare system, especially in the underserved area of mental health. At the same time, the platform empowers users with greater personal responsibility and control over their health journey.

By using real-time biomarker data, PanGenomic deliberately sets itself apart from purely static health apps and creates a dynamic adaptation process.

Through its subsidiary Mindleap Health, the Company is currently driving forward the development of an evidence-based data platform for complementary medicine applications. This platform will collect and evaluate health data from various sources in order to better document the effectiveness of non-pharmaceutical approaches globally. In the long term, this could help to scientifically substantiate and expand the entire market for alternative health solutions. The platform uses modern large language models to systematically evaluate even non-traditional data sources such as historical application data and modern user reports.

In addition, PanGenomic recently expanded its e-commerce strategy and launched the Agenta Health platform. The Company leverages this channel to sell personalized health products and plans to further refine the recommendation function through an AI-based interface. In doing so, it combines digital diagnostics, telemedicine, and data-driven e-commerce into an integrated ecosystem, clearly setting itself apart from pure wellness providers. The shop serves as a practical implementation of personalized recommendations and creates an additional revenue stream. Since the end of May, the share price has risen by over 1,000% at its peak. The share is currently trading at CAD 2.19.

Pfizer – Uncertainty dominates

Pfizer is increasingly positioning itself as a player in the future market of digital health. With the Pfizer Healthcare Hub, the Company has created a platform that promotes digital and technological innovation. The aim is to collect more data about customers and build greater loyalty among patients, which should open up new sources of revenue in the long term. Collaborations, such as with Alex Therapeutics for digital smoking cessation or with Ada Health for AI-supported diagnostic aids, underscore this approach.

Beyond its digital ambitions, established therapies are supporting the business. Growth drivers such as the blood thinner Eliquis and the Vyndaqel series of amyloidosis drugs are recording double-digit growth. The oncology division, fueled by the acquisition of the Seagen portfolio, is also growing strongly. These solid core businesses are partially offsetting the expected decline in COVID-19 revenues. However, price pressure in the US is weighing on the entire industry.

Despite declining overall revenues in the wake of the pandemic, Pfizer remains financially robust. Margins are respectable, and the dividend yield is attractive. However, political uncertainties, such as possible regulatory intervention in the US, are among the risks that investors should keep an eye on. The high payout ratio requires a stable earnings base, which will be challenged by upcoming patent expiries from 2026 onwards. For investors seeking reliable dividends and exposure to a broad pipeline, Pfizer remains an interesting, albeit not risk-free, investment. The share is currently trading at USD 23.90.

The healthcare revolution in digital health rewards strategy and agility. Novo Nordisk is fundamentally restructuring itself to grow in the digital ecosystem beyond pure pharmaceutical products. PanGenomic Health is driving data-driven personalization in medicine with AI-driven, personalized platforms. Pfizer, on the other hand, must overcome political and market uncertainties while simultaneously advancing its digital transformation.